<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306826</url>
  </required_header>
  <id_info>
    <org_study_id>Leipzig-01</org_study_id>
    <nct_id>NCT00306826</nct_id>
  </id_info>
  <brief_title>Pioglitazone in Impaired Glucose Tolerance</brief_title>
  <official_title>Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut für Gesundheits- und Praxismanagement GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <brief_summary>
    <textblock>
      In patients with impaired glucose tolerance (IGT), the researchers want to study the relative
      effects of pioglitazone, simvastatin, or the combination of both on:

        -  intima media thickness (IMT) as an easily assessed marker of atherosclerosis

        -  heart rate variability (HRV) as a marker of autonomic neuropathy

        -  flow-mediated vasodilatation (FMD) of the brachial artery as a marker of endothelial
           function

        -  vascular and metabolic lab parameters
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We want to study the relative effects of pioglitazone, simvastatin or the combination of both
      on intima media thickness (IMT), heart rate variability (HRV), flow-mediated vasodilatation
      (FMD) of the brachial artery and vascular/metabolic lab parameters in patients with impaired
      glucose tolerance (IGT). Previous studies have shown a reduction in IMT for both pioglitazone
      and simvastatin in type 2 diabetics. Many patients with diabetes mellitus develop diabetic
      polyneuropathy which can be assessed by measuring HRV. It has been shown that pioglitazone
      has a positive effect on HRV in type 2 diabetics. Questions remain on the relative efficacy
      of pioglitazone and simvastatin on the parameters mentioned above. Also, there is only scarce
      data in patients with IGT (as opposed to overt diabetes mellitus). There are no data on the
      relative effects of pioglitazone and simvastatin on flow-mediated vasodilatation (FMD) of the
      brachial artery as a surrogate marker for endothelial function.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    financial support withdrawn
  </why_stopped>
  <completion_date>May 2009</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intima media thickness of carotid artery</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated dilatation of brachial artery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular/metabolic lab parameters</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone + simvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaired glucose tolerance

          -  Age 40 to 75 years

        Exclusion Criteria:

          -  Diabetes mellitus type 1 or 2

          -  Hypersensitivity to study medication

          -  Malignant tumor

          -  Alcohol or drug abuse

          -  Overt heart failure

          -  Severe hepatic, renal, neurological, psychiatric, or hematological disease

          -  Prior treatment with glitazones or statins

          -  Established indication for statin treatment (e.g. coronary artery disease [CAD])
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Schuler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis Antje Horn</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Gunter Kässner</name>
      <address>
        <city>Leipzig</city>
        <zip>04229</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Heidrun Täschner</name>
      <address>
        <city>Leipzig</city>
        <zip>04249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Martin Schönauer</name>
      <address>
        <city>Leipzig</city>
        <zip>04275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Matthias Weissbrodt</name>
      <address>
        <city>Leipzig</city>
        <zip>04299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Matthias Schreiner</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2006</study_first_submitted>
  <study_first_submitted_qc>March 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2006</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <keyword>Impaired glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

